CN114053395A - 用于治疗纤维化癌症的方法 - Google Patents

用于治疗纤维化癌症的方法 Download PDF

Info

Publication number
CN114053395A
CN114053395A CN202111292205.8A CN202111292205A CN114053395A CN 114053395 A CN114053395 A CN 114053395A CN 202111292205 A CN202111292205 A CN 202111292205A CN 114053395 A CN114053395 A CN 114053395A
Authority
CN
China
Prior art keywords
sap
treatment
cancer
myelofibrosis
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111292205.8A
Other languages
English (en)
Chinese (zh)
Inventor
S·布鲁恩
E·特里胡
M·鲁普赫尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Promedior Inc
Original Assignee
Promedior Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promedior Inc filed Critical Promedior Inc
Publication of CN114053395A publication Critical patent/CN114053395A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716—Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202111292205.8A 2013-10-08 2014-10-08 用于治疗纤维化癌症的方法 Pending CN114053395A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361888269P 2013-10-08 2013-10-08
US61/888,269 2013-10-08
US201461992807P 2014-05-13 2014-05-13
US61/992,807 2014-05-13
US201462004828P 2014-05-29 2014-05-29
US201462004836P 2014-05-29 2014-05-29
US62/004,828 2014-05-29
US62/004,836 2014-05-29
CN201480062728.5A CN105792831A (zh) 2013-10-08 2014-10-08 用于治疗纤维化癌症的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480062728.5A Division CN105792831A (zh) 2013-10-08 2014-10-08 用于治疗纤维化癌症的方法

Publications (1)

Publication Number Publication Date
CN114053395A true CN114053395A (zh) 2022-02-18

Family

ID=52813618

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111292205.8A Pending CN114053395A (zh) 2013-10-08 2014-10-08 用于治疗纤维化癌症的方法
CN201480062728.5A Pending CN105792831A (zh) 2013-10-08 2014-10-08 用于治疗纤维化癌症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480062728.5A Pending CN105792831A (zh) 2013-10-08 2014-10-08 用于治疗纤维化癌症的方法

Country Status (10)

Country Link
US (2) US11020451B2 (enExample)
EP (2) EP3054959B1 (enExample)
JP (2) JP6636914B2 (enExample)
CN (2) CN114053395A (enExample)
AU (2) AU2014331954B2 (enExample)
CA (1) CA2926418A1 (enExample)
ES (1) ES2784234T3 (enExample)
PL (1) PL3054959T3 (enExample)
RU (2) RU2020111934A (enExample)
WO (1) WO2015054390A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2020111934A (ru) 2013-10-08 2020-04-29 Промедиор, Инк. Способы лечения фиброзного рака
US20180318303A1 (en) * 2015-04-15 2018-11-08 Promedior, Inc. Methods for treating myeloproliferative disorders
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
SG11202006782YA (en) * 2018-01-31 2020-08-28 Twi Pharmaceuticals Inc Topical formulations comprising tofacitinib
CA3093749A1 (en) * 2018-03-28 2019-10-03 Blade Therapeutics, Inc. Method of treating fibrotic disease
CN108715865B (zh) * 2018-05-28 2021-09-21 福建师范大学 用于提高细胞转染效率的试剂组合物
CA3128081A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
US20220202803A1 (en) * 2019-04-25 2022-06-30 Clear Creek Bio, Inc. Combination therapies including inhibitors of dihydroorotate dehydrogenase
CN112107556A (zh) * 2019-06-03 2020-12-22 北京大学 一种含砷纳米药物及其制备方法
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
US20230089484A1 (en) * 2020-01-28 2023-03-23 Raziel Therapeutics Ltd. Compositions for the treatment of angiolipoma
KR102725907B1 (ko) * 2021-11-25 2024-11-04 성균관대학교산학협력단 파크리티닙을 이용한 항암제 내성 암 치료를 위한 병용 요법
AU2024239074A1 (en) * 2023-03-17 2025-10-02 Mdx Management Llc Compositions and methods for ameliorating adverse effects of therapies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101166539A (zh) * 2005-02-08 2008-04-23 得克萨斯大学体系董事会 用于治疗癌症的涉及mda-7的组合物和方法
CN102574902A (zh) * 2009-06-04 2012-07-11 普罗麦迪奥股份有限公司 血清淀粉样蛋白p衍生物及其制备和用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
EP0786522A2 (en) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecules for treatment of stenotic conditions
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
WO1999004819A1 (en) 1997-07-24 1999-02-04 Inex Pharmaceuticals Corporation Liposomal compositions for the delivery of nucleic acid catalysts
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US7763256B2 (en) 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
US8012472B2 (en) * 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
EP1711196A4 (en) 2003-12-05 2011-09-14 Bristol Myers Squibb Co INHIBITORS OF TYPE-2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
ES2599319T3 (es) * 2006-06-26 2017-02-01 Macrogenics, Inc. Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
ES2409756T3 (es) * 2006-12-04 2013-06-27 Promedior, Inc. Combinación de SAP y de enalapril para su uso en tratamiento de trastornos fibróticos o fibroproliferativos
PL2185581T3 (pl) * 2007-07-06 2016-01-29 Promedior Inc Sposoby i kompozycje użyteczne do leczenia zapalenia błony śluzowej
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) * 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
CA2754961C (en) 2009-03-11 2018-04-10 Promedior, Inc. Treatment and diagnostic methods for hypersensitive disorders
EP2405929B1 (en) * 2009-03-11 2018-06-06 Promedior Inc. A sap polypeptide for use in the treatment of autoimmune disorders and graft vs host disease
JP2012522798A (ja) 2009-04-01 2012-09-27 プロメディオール， インコーポレイテッド 血清アミロイドｐの肺および鼻への送達
EP2987803B1 (en) 2009-06-17 2018-08-29 Promedior Inc. Sap variants and their use
ES2728446T3 (es) 2011-12-21 2019-10-24 Promedior Inc Proteínas de fusión de P-anticuerpos de amiloide sérico
JP2015069119A (ja) 2013-09-30 2015-04-13 パナソニック液晶ディスプレイ株式会社 表示装置
RU2020111934A (ru) 2013-10-08 2020-04-29 Промедиор, Инк. Способы лечения фиброзного рака
US20180318303A1 (en) 2015-04-15 2018-11-08 Promedior, Inc. Methods for treating myeloproliferative disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101166539A (zh) * 2005-02-08 2008-04-23 得克萨斯大学体系董事会 用于治疗癌症的涉及mda-7的组合物和方法
CN102574902A (zh) * 2009-06-04 2012-07-11 普罗麦迪奥股份有限公司 血清淀粉样蛋白p衍生物及其制备和用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALEX GANETSKY: ""Ruxolitinib: A New Treatment Option for Myelofibrosis"", 《PHARMACOTHERAPY》, vol. 33, no. 1, 10 January 2013 (2013-01-10), pages 84 - 92, XP055352706, DOI: 10.1002/phar.1165 *

Also Published As

Publication number Publication date
AU2014331954B2 (en) 2020-05-21
JP2020059752A (ja) 2020-04-16
JP6636914B2 (ja) 2020-01-29
AU2020220139A1 (en) 2020-09-10
CA2926418A1 (en) 2015-04-16
RU2016117775A (ru) 2017-11-15
EP3054959B1 (en) 2020-01-08
US20210322515A1 (en) 2021-10-21
JP2016539087A (ja) 2016-12-15
AU2014331954A1 (en) 2016-04-21
US11020451B2 (en) 2021-06-01
EP3054959A4 (en) 2017-04-26
US20160235812A1 (en) 2016-08-18
PL3054959T3 (pl) 2020-07-13
JP7140739B2 (ja) 2022-09-21
CN105792831A (zh) 2016-07-20
EP3054959A1 (en) 2016-08-17
RU2020111934A (ru) 2020-04-29
EP3718558A1 (en) 2020-10-07
RU2718056C2 (ru) 2020-03-30
WO2015054390A1 (en) 2015-04-16
RU2016117775A3 (enExample) 2018-07-27
ES2784234T3 (es) 2020-09-23

Similar Documents

Publication Publication Date Title
JP7140739B2 (ja) 線維性癌の治療方法
JP2018512164A (ja) 骨髄増殖性障害を処置するための方法
EP2525824B1 (en) Inhibition of axl signaling in anti-metastatic therapy
KR102810368B1 (ko) 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법
EP3092250A1 (en) Polynucleotides for the in vivo production of antibodies
JP2018522039A (ja) 骨髄増殖性障害を処置するための方法
JP2022509445A (ja) 線維症を治療又は予防するための組成物及び方法
CN109789210A (zh) 用于治疗癌症的胰高血糖素受体拮抗剂和pi3k途径抑制剂的组合
CN117083381A (zh) 用于靶向炎性细胞或活化细胞和治疗或改善炎性病症和疼痛的组合物和方法
CN104995207B (zh) β整联蛋白-G蛋白α亚基结合相互作用的抑制剂
JP2018528210A (ja) グルカゴン受容体アンタゴニスト抗体を用いた心不全の治療法
HK40069679A (en) Methods for treating fibrotic cancers
HK40039408A (en) Methods for treating fibrotic cancers
JP5393691B2 (ja) 急性ヒト骨髄性白血病細胞を死滅させるトロンボポエチン受容体作用薬（ＴｐｏＲＡ）
WO2014093870A2 (en) Use of c-c chemokine receptor type 7 (ccr7) inhibitors
Salzman et al. Novel Strategies Targeting Mutant Calreticulin in Essential Thrombocythemia and Myelofibrosis
US10213481B2 (en) Compositions and methods to treat inflammatory joint disease
HK1226660B (en) Methods for treating fibrotic cancers
HK1226660A1 (en) Methods for treating fibrotic cancers
US20170319657A1 (en) Method of treating a bladder cancer using a chimeric egf-targeted bacterial toxin
WO2025250689A1 (en) Combination therapy with angiogenesis protein and immune checkpoint inhibitor with/without chemotherapeutics
WO2023233665A1 (ja) 免疫細胞の活性化剤、及び免疫細胞関連炎症疾患の治療剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40069679

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220218